354 related articles for article (PubMed ID: 18440031)
21. Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma.
Guillamo JS; de Boüard S; Valable S; Marteau L; Leuraud P; Marie Y; Poupon MF; Parienti JJ; Raymond E; Peschanski M
Clin Cancer Res; 2009 Jun; 15(11):3697-704. PubMed ID: 19435839
[TBL] [Abstract][Full Text] [Related]
22. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.
Buck E; Eyzaguirre A; Rosenfeld-Franklin M; Thomson S; Mulvihill M; Barr S; Brown E; O'Connor M; Yao Y; Pachter J; Miglarese M; Epstein D; Iwata KK; Haley JD; Gibson NW; Ji QS
Cancer Res; 2008 Oct; 68(20):8322-32. PubMed ID: 18922904
[TBL] [Abstract][Full Text] [Related]
23. Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma.
Liu Y; Poon RT; Shao W; Sun X; Chen H; Kok TW; Fan ST
Cancer Lett; 2007 Apr; 248(1):32-40. PubMed ID: 16837130
[TBL] [Abstract][Full Text] [Related]
24. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
25. Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity.
Rosanò L; Di Castro V; Spinella F; Tortora G; Nicotra MR; Natali PG; Bagnato A
Cancer Res; 2007 Jul; 67(13):6351-9. PubMed ID: 17616694
[TBL] [Abstract][Full Text] [Related]
26. The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels.
Iivanainen E; Lauttia S; Zhang N; Tvorogov D; Kulmala J; Grenman R; Salven P; Elenius K
Microvasc Res; 2009 Dec; 78(3):278-85. PubMed ID: 19596357
[TBL] [Abstract][Full Text] [Related]
27. ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839).
Djerf EA; Trinks C; Abdiu A; Thunell LK; Hallbeck AL; Walz TM
Melanoma Res; 2009 Jun; 19(3):156-66. PubMed ID: 19434003
[TBL] [Abstract][Full Text] [Related]
28. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice.
Kim SJ; Uehara H; Karashima T; Shepherd DL; Killion JJ; Fidler IJ
Clin Cancer Res; 2003 Mar; 9(3):1200-10. PubMed ID: 12631626
[TBL] [Abstract][Full Text] [Related]
29. EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells.
Grøvdal LM; Kim J; Holst MR; Knudsen SL; Grandal MV; van Deurs B
Cell Signal; 2012 Jan; 24(1):296-301. PubMed ID: 21951604
[TBL] [Abstract][Full Text] [Related]
30. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo.
Bruzzese F; Di Gennaro E; Avallone A; Pepe S; Arra C; Caraglia M; Tagliaferri P; Budillon A
Clin Cancer Res; 2006 Jan; 12(2):617-25. PubMed ID: 16428508
[TBL] [Abstract][Full Text] [Related]
31. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.
Hickinson DM; Klinowska T; Speake G; Vincent J; Trigwell C; Anderton J; Beck S; Marshall G; Davenport S; Callis R; Mills E; Grosios K; Smith P; Barlaam B; Wilkinson RW; Ogilvie D
Clin Cancer Res; 2010 Feb; 16(4):1159-69. PubMed ID: 20145185
[TBL] [Abstract][Full Text] [Related]
32. (-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis.
Shirakami Y; Shimizu M; Adachi S; Sakai H; Nakagawa T; Yasuda Y; Tsurumi H; Hara Y; Moriwaki H
Cancer Sci; 2009 Oct; 100(10):1957-62. PubMed ID: 19558547
[TBL] [Abstract][Full Text] [Related]
33. AEE788, a dual tyrosine kinase receptor inhibitor, induces endothelial cell apoptosis in human cutaneous squamous cell carcinoma xenografts in nude mice.
Park YW; Younes MN; Jasser SA; Yigitbasi OG; Zhou G; Bucana CD; Bekele BN; Myers JN
Clin Cancer Res; 2005 Mar; 11(5):1963-73. PubMed ID: 15756022
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647.
Gendreau SB; Ventura R; Keast P; Laird AD; Yakes FM; Zhang W; Bentzien F; Cancilla B; Lutman J; Chu F; Jackman L; Shi Y; Yu P; Wang J; Aftab DT; Jaeger CT; Meyer SM; De Costa A; Engell K; Chen J; Martini JF; Joly AH
Clin Cancer Res; 2007 Jun; 13(12):3713-23. PubMed ID: 17575237
[TBL] [Abstract][Full Text] [Related]
35. Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling.
Normanno N; Campiglio M; Maiello MR; De Luca A; Mancino M; Gallo M; D'Alessio A; Menard S
Breast Cancer Res Treat; 2008 Nov; 112(1):25-33. PubMed ID: 18060492
[TBL] [Abstract][Full Text] [Related]
36. Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib.
Cunningham MP; Thomas H; Fan Z; Modjtahedi H
Cancer Res; 2006 Aug; 66(15):7708-15. PubMed ID: 16885373
[TBL] [Abstract][Full Text] [Related]
37. Activation of MEK/ERK and PI3K/Akt pathways by fibronectin requires integrin alphav-mediated ADAM activity in hepatocellular carcinoma: a novel functional target for gefitinib.
Matsuo M; Sakurai H; Ueno Y; Ohtani O; Saiki I
Cancer Sci; 2006 Feb; 97(2):155-62. PubMed ID: 16441427
[TBL] [Abstract][Full Text] [Related]
38. Cyclooxygenase-2 (COX-2) negatively regulates expression of epidermal growth factor receptor and causes resistance to gefitinib in COX-2-overexpressing cancer cells.
Kim YM; Park SY; Pyo H
Mol Cancer Res; 2009 Aug; 7(8):1367-77. PubMed ID: 19671676
[TBL] [Abstract][Full Text] [Related]
39. ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase.
Hirata A; Ogawa S; Kometani T; Kuwano T; Naito S; Kuwano M; Ono M
Cancer Res; 2002 May; 62(9):2554-60. PubMed ID: 11980649
[TBL] [Abstract][Full Text] [Related]
40. Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.
Bianco R; Caputo R; Caputo R; Damiano V; De Placido S; Ficorella C; Agrawal S; Bianco AR; Ciardiello F; Tortora G
Clin Cancer Res; 2004 Jul; 10(14):4858-64. PubMed ID: 15269162
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
